Recursion's approach is intriguing, as evidenced by the fact that several of the world's largest pharmaceutical companies ...
Recursion CEO Chris Gibson is out after 12 years as the ambitious "techbio" company positions itself for its next phase of AI drug discovery.
Salt Lake City, Utah, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that its Board ...
Recursion Pharmaceuticals, Inc (($RXRX)) has held its Q3 earnings call. Read on for the main highlights of the call. Recursion Pharmaceuticals, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback